{"slug":"tirzepatide-glp1-agonists","verification":{"valid":true,"entries":4,"head":"9dd3bcbb97328c1fc2d8a1364dcef10d23a55dc08a478163e849d2f5b32aa4ae"},"count":4,"models":["grok-4.3"],"yield":{"passes":4,"energy_spent_rows":0,"total_cost_usd":0,"waste_cost_usd":0,"total_tokens":0,"material_outputs":0,"usd_per_output":null,"models":[{"model":"grok-4.3","passes":4,"cost_usd":0,"tokens_total":0,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T17:45:19.067Z","model":"grok-4.3","role":"writer","action":"draft","payload":{"title":"tirzepatide glp1 agonists","register":"standard","body":"## Overview\nEvidence is being populated by Grok web search.","claims":[],"sources":[]},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"genesis","hash":"e5e165ce2e7869e9322d63cb6d5e34ae48a118b338e65edaf378303a048553cb"},{"seq":1,"id":"k2","ts":"2026-06-29T17:45:37.076Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40746703/","title":"Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration","quote":"A dose-dependent tirzepatide was superior to placebo and GLP-1 RAs in weight reduction. However, the lean mass reduction and tolerability require further investigation.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42119587/","title":"Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial","quote":"We evaluated the efficacy and safety of continuing tirzepatide at the maximum tolerated dose (MTD) or lowering the dose to 5 mg compared with placebo.","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT06820281","title":"Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes","quote":"This mechanistic study will define mechanisms by which GLP1-GIP co-agonism may uniquely provide clinical benefits in T1D during the fasting and fed states.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40353578/","title":"Tirzepatide as Compared with Semaglutide for the Treatment of Obesity","quote":"Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight.","link_status":"ok","quote_status":"unverified"},{"id":"s5","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41264593/","title":"Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Clinical Trial","quote":"Among adults with type 1 diabetes and obesity, tirzepatide was superior to placebo for weight loss over 12 weeks.","link_status":"ok","quote_status":"verified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"e5e165ce2e7869e9322d63cb6d5e34ae48a118b338e65edaf378303a048553cb","hash":"2abbdfb3c94910d6277440b303207e797bab2a4e1fa4b3303f5feeb13d1a74c5"},{"seq":2,"id":"k3","ts":"2026-06-29T17:45:54.298Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s6","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/41761267/","title":"Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis","quote":"These findings suggest that tirzepatide provides cardiovascular benefit at least comparable to established GLP-1RAs, supporting its emerging role in cardiovascular risk reduction in T2D.","link_status":"ok","quote_status":"verified"},{"id":"s7","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42168641/","title":"Causes and consequences of discontinuation of GLP1RAs and tirzepatide","quote":"In this Review, we discuss common reasons for GLP1R agonist and tirzepatide discontinuation and examine available evidence related to potential cardiometabolic ...","link_status":"ok","quote_status":"unverified"},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41655764/","title":"Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists","quote":"Among patients with T2D taking a GLP-1 RA, tirzepatide was associated with lower risks of retinal complications, need for vision-saving ...","link_status":"ok","quote_status":"unverified"},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41936548/","title":"Weight Loss With GLP-1 Agonists in Nondiabetic Adults","quote":"Tirzepatide, particularly at higher doses, provides the greatest weight reduction in adults without diabetes.","link_status":"ok","quote_status":"verified"}]},"rationale":"auto-populate round 2","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"2abbdfb3c94910d6277440b303207e797bab2a4e1fa4b3303f5feeb13d1a74c5","hash":"478f0feeeb323592e6948479c864d2ae36141424e5a9eb687f0faf92beb79138"},{"seq":3,"id":"k4","ts":"2026-06-29T17:46:47.571Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s10","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39536238/","title":"Tirzepatide for Obesity Treatment and Diabetes Prevention","quote":"Three years of treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a markedly ...","link_status":"ok","quote_status":"unverified"},{"id":"s11","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39996368/","title":"Real-world use and effectiveness of tirzepatide among ...","quote":"To understand real-world tirzepatide utilization and effectiveness (change in weight and body mass index [BMI]) among people without type 2 diabetes (T2D) in ...","link_status":"ok","quote_status":"unverified"},{"id":"s12","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41354867/","title":"A real-world study of tirzepatide for weight loss in adults ...","quote":"In this prospective multicentre observational study, 115 adults with obesity but without diabetes were treated with tirzepatide 2.5 mg weekly for 4 weeks, ...","link_status":"ok","quote_status":"unverified"},{"id":"s13","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40630338/","title":"Dose-Dependent Efficacy and Safety of Tirzepatide for ...","quote":"Tirzepatide produces substantial, dose-dependent weight loss and improves metabolic and quality-of-life outcomes in obese adults without diabetes.","link_status":"ok","quote_status":"verified"},{"id":"s14","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41196501/","title":"Insights into the Mechanism of Action of Tirzepatide","quote":"Here, we review the mechanistic activity of tirzepatide and its effect on glycemic control, body weight, the cardiorenal system, and lipid metabolism.","link_status":"ok","quote_status":"verified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"478f0feeeb323592e6948479c864d2ae36141424e5a9eb687f0faf92beb79138","hash":"9dd3bcbb97328c1fc2d8a1364dcef10d23a55dc08a478163e849d2f5b32aa4ae"}]}